SLC5A6

SLC5A6 encodes SMVT, a Na+-coupled symporter that serves as the major physiological route for cellular uptake of biotin and pantothenic acid, and is the sole carrier for intestinal biotin absorption in vivo (PMID:12646417, PMID:23104561, PMID:25809983). The same transporter also mediates Na+-coupled iodide influx through a mechanism distinct from NIS, being insensitive to perchlorate and instead inhibited competitively by its own organic substrates (PMID:20980265). SMVT is preferentially positioned at the luminal/apical membrane of polarized epithelium and barrier endothelium, where it accounts for the overwhelming majority of biotin and pantothenate transport at the intestinal, retinal, and brain capillary barriers (PMID:20599968, PMID:25809983); correct trafficking to this membrane is essential, as loss-of-function mutations cause cytoplasmic or ER retention with abolished transport (PMID:27904971). Because its substrates are precursors for biotin- and CoA-dependent metabolism, loss of SMVT function disrupts mitochondrial CoA synthesis and energy metabolism, an effect that drives dilated cardiomyopathy upon cardiac-specific deletion and defective B cell/plasma cell maturation with antibody deficiency in patients, both reversible by biotin/pantothenate supplementation (PMID:42228401, PMID:38036278). In the intestine, SMVT loss compromises tight-junction integrity and mucosal barrier function, triggering NF-κB and NLRP3 inflammasome activation driven by gut microbiota, with growth retardation and premature death rescued by biotin and pantothenic acid (PMID:23104561, PMID:27492331, PMID:29669219, PMID:31369292). SMVT expression is feedback-regulated by holocarboxylase synthetase, which biotinylates histone H4 at lysine 12 at the SLC5A6 promoter to silence transcription in proportion to biotin availability (PMID:17904341). In cancer, SMVT-mediated biotin import sustains a biotin→ACC→FASN lipid-metabolism axis that promotes tumor growth (PMID:39426496, PMID:41108787). Pathogenic SLC5A6 variants—nonsense, missense, and splice-disrupting alleles—reduce transporter expression or activity and are functionally validated by impaired biotin uptake (PMID:27904971, PMID:38816490).

1. 2003 High

   Established that SMVT, not a postulated second high-affinity system, is the dominant physiological biotin uptake route in human intestinal and hepatic epithelia, defining its primary transport function.

   Evidence siRNA knockdown of SMVT with [3H]biotin uptake assays in Caco-2 and HepG2 cells

   PMID:12646417

   Open questions at the time

   • Did not address pantothenate or lipoate uptake
   • In vitro cell lines only; in vivo contribution not yet tested
2. 2007 Medium

   Revealed a feedback loop in which biotin status, sensed by HCS, controls SMVT transcription via histone H4K12 biotinylation at the promoter, explaining how the transporter is downregulated under biotin sufficiency.

   Evidence ChIP for HCS and K12Bio H4 at SMVT promoters in Jurkat cells across biotin concentrations, plus HCS knockdown

   PMID:17904341

   Open questions at the time

   • Single lab and cell type
   • Mechanism of HCS recruitment to the promoter unresolved
3. 2010 Medium

   Defined the substrate breadth of SMVT by showing it transports iodide via a Na+-coupled mechanism mechanistically separable from the NIS symporter, and confirmed concentration-dependent biotin transport at the blood-retinal barrier.

   Evidence Functional transport and substrate-competition assays in hSMVT-expressing cells; in vivo retinal uptake and TR-iBRB2 cell assays

   PMID:20599968 PMID:20980265

   Open questions at the time

   • Physiological relevance of SMVT-mediated iodide transport unestablished
   • Stoichiometry of Na+ coupling not quantified
4. 2012 High

   Genetic proof in vivo that SMVT is solely responsible for intestinal biotin absorption, linking its loss to growth failure, bone defects, intestinal inflammation, and death.

   Evidence Intestine-specific Cre/lox Slc5a6 conditional knockout mice with in vivo/in vitro transport, histology, and bone density

   PMID:23104561

   Open questions at the time

   • Did not separate biotin vs pantothenate contributions to phenotype
   • Mechanism linking deficiency to inflammation not yet defined
5. 2012 Medium

   Extended SMVT transport function to cancer cells and uncovered calcium-calmodulin regulation of its activity.

   Evidence Kinetic [3H]biotin uptake assays with pharmacological pathway inhibitors in T47D breast cancer cells; SMVT localization to the Chlamydia inclusion membrane by immunofluorescence

   PMID:23029384 PMID:23142496

   Open questions at the time

   • Calmodulin regulatory mechanism not molecularly defined
   • Pathogen subversion of SMVT not tested for pantothenate/lipoate directly
6. 2015 High

   Quantified SMVT's dominant contribution to barrier transport and pinned its luminal localization in human brain capillary endothelium.

   Evidence Quantitative targeted absolute proteomics, antibody-free membrane localization, siRNA knockdown, and uptake assays in hCMEC/D3 cells

   PMID:25809983

   Open questions at the time

   • Mechanism of apical/luminal targeting not defined
   • NSAID/PGE2 inhibition mechanism unresolved
7. 2016 Medium

   Demonstrated that human loss-of-function mutations disrupt SMVT trafficking, establishing that membrane delivery is required for transport activity and linking specific variants to impaired biotin uptake.

   Evidence [3H]biotin uptake and live-cell confocal imaging of R94X and R123L mutants in HuTu-80 and U87 cells

   PMID:27904971

   Open questions at the time

   • Clinical phenotype of carriers not fully characterized
   • Trafficking machinery interacting with SMVT unidentified
8. 2016 Medium

   Connected SMVT loss to breakdown of intestinal barrier integrity via altered tight-junction proteins, attributing the defect specifically to biotin insufficiency.

   Evidence Conditional SMVT-KO mice and dietary biotin-deficiency in wild-type mice with permeability and tight-junction protein assays

   PMID:27492331

   Open questions at the time

   • Molecular link between biotin and tight-junction regulation unresolved
   • Single lab
9. 2018 Medium

   Causally proved the intestinal phenotype is due to vitamin transport loss by rescuing survival, growth, and inflammation with biotin/pantothenate supplementation.

   Evidence Biotin/pantothenic acid drinking-water supplementation rescue in SMVT-cKO mice with survival, histology, and inflammation readouts

   PMID:29669219

   Open questions at the time

   • Relative contributions of biotin vs pantothenate not separated
   • Downstream metabolic targets not identified here
10. 2019 Medium

    Identified the gut microbiota as the driver of inflammation in SMVT loss, acting through NF-κB and NLRP3 inflammasome signaling.

    Evidence Tamoxifen-inducible intestine-specific SMVT-icKO mice with pathway analysis and broad-spectrum antibiotic rescue

    PMID:31369292

    Open questions at the time

    • Specific microbial taxa or metabolites not identified
    • Link between vitamin deficiency and microbiota shift undefined
11. 2023 Medium

    Established a role in adaptive immunity, showing SLC5A6 mutations impair B cell differentiation and antibody production via biotin-dependent mitochondrial metabolism, rescuable by biotin.

    Evidence Exome sequencing, CRISPR-Cas9 mouse with patient variants, B cell/plasma cell assays, metabolic profiling, and biotin replenishment

    PMID:38036278

    Open questions at the time

    • Mechanism linking biotin to plasma cell metabolic switch incomplete
    • Single patient lineage
12. 2024 High

    Defined a cardiac requirement for SMVT, with deletion causing dilated cardiomyopathy through impaired CoA synthesis and mitochondrial metabolic disruption, fully preventable by vitamin supplementation.

    Evidence Cardiac-specific Slc5a6 knockout mice with MRI, ECG, histology, proteomics, CoA assays, and supplementation rescue

    PMID:42228401

    Open questions at the time

    • Cardiomyocyte-autonomous vs systemic contributions not fully separated
    • Pantothenate-specific role in CoA defect quantified but mechanism upstream not detailed
13. 2024 Medium

    Functionally validated additional pathogenic SLC5A6 alleles, linking splice-disrupting and missense variants to reduced mRNA or transport activity.

    Evidence RT-PCR splice analysis and [3H]biotin uptake in patient fibroblasts plus genome sequencing

    PMID:38816490

    Open questions at the time

    • Full disease spectrum across variants not delineated
    • Single study
14. 2024 Medium

    Placed SLC5A6 upstream of a biotin→ACC→FASN lipid-metabolism axis in lung adenocarcinoma and identified Foxd3 as a transcriptional regulator, defining a pro-tumor function.

    Evidence SLC5A6 knockout/overexpression in LUAD cells, transcriptomics, FASN knockdown rescue, and xenografts; Foxd3 analysis

    PMID:39426496

    Open questions at the time

    • Direct Foxd3 binding to SLC5A6 promoter not shown
    • Single lab
15. 2025 Medium

    Generalized the SLC5A6-ACC-FASN lipid axis to cervical cancer and refined SMVT substrate selectivity, showing certain biotin derivatives bypass the transporter.

    Evidence SLC5A6 knockdown/overexpression in HeLa/SiHa with FASN rescue and xenografts; comparative uptake of biotin derivatives in SLC5A6-inactivated HEK293 cells

    PMID:41108787 PMID:41122322

    Open questions at the time

    • Alternative biotin-derivative transporters not identified
    • Therapeutic exploitability of the ACC-FASN axis untested

• The structural basis of substrate recognition and Na+ coupling, the machinery directing apical/luminal trafficking, and the mechanistic link between SMVT vitamin transport and tissue-specific outcomes (tight junctions, plasma cell metabolism, microbiota) remain unresolved.
• No high-resolution structure or transport stoichiometry
• Trafficking/sorting determinants unidentified
• Mechanistic bridge from biotin/pantothenate supply to each downstream phenotype incomplete